Skip to main content
AAO-HNSF 2023 Annual Meeting & OTO Experience Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Rate ePoster

Head and Neck Surgery

(273) Intensified Adjuvant Treatment for Resected Head and Neck Angiosarcoma

Monday, October 2, 2023
2:45 PM – 3:45 PM East Coast USA Time
Has Audio

    Presenting Author(s)

  • Muhammad El Shatanofy, MD

    Resident Physician
    University of Miami
    Miami, Florida, United States

    • Co-Author(s)

  • PT

    Punam Thakkar, MD

    Associate Professor
    The George Washington University Medical Faculty Associates, Department of Otolaryngology
    Washington, District of Columbia, USA

  • VP

    Vishal Patel, MD

    Assistant Professor
    The George Washington University Medical Faculty Associates, Department of Dermatology, USA

  • AJ

    Arjun S. Joshi, MD

    Professor of Surgery
    The George University Medical Faculty Associates, Department of Otolaryngology
    Washington, DC, United States

  • Joseph F. Goodman, MD

    Associate Professor
    The George Washington University Medical Faculty Associates, Department of Otolaryngology
    Washington, District of Columbia, United States

    • Senior Author(s)

  • YR

    Yuan Rao, MD

    Assistant Professor
    The George Washington University Medical Faculty Associates, Department of Radiation Oncology, USA

Disclosure(s):
Muhammad El Shatanofy, MD: No relevant relationships to disclose.
Arjun S. Joshi, MD: No relevant relationships to disclose.
Joseph F. Goodman, MD: No relevant relationships to disclose.


Introduction: Previous studies have highlighted the poor survival of patients with cutaneous angiosarcoma of the head and neck. Therapeutic options are limited, and effective treatment strategies are yet to be discovered. The objective of this study is to evaluate overall survival following intensified adjuvant treatment for high risk resected angiosarcoma of the head and neck.

Methods: Patients diagnosed with non-metastatic cutaneous angiosarcoma of the head and neck from 2004 to 2016 were identified from the National Cancer Database (NCDB). We retrospectively compared demographics and overall survival between patients who received surgery and radiation therapy (SR) and patients who received surgery and chemoradiation (SRC). The χ2 test, Kaplan-Meier method, and Cox regression models were used to analyze data.

Results: A total of 249 patients were identified, of which 79.5% were treated with surgery and radiation alone and 20.5% were treated with surgery and chemoradiation. The addition of chemotherapy, regardless of sequence of administration, did not significantly improve overall survival. Factors associated with worse survival in both groups included older age, positive nodal status, and positive margins. Patients with positive nodes had improved survival with radiation doses > 50.4 Gy compared to ≤ 50.4 Gy (HR: 2.93, CI: 1.60 – 5.36, p < 0.001).

Conclusions: Adjuvant chemotherapy does not seem to impact overall survival for resected non-metastatic angiosarcoma of the head and neck. Higher radiation doses are prognostic for high-risk disease.